SCHEMBL25307247

SCHEMBL25307247

Cc1ccc(S(=O)(=O)OC[C@H]2CC[C@@](C)(O)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.40
STAT3 P40763 1/20 0.39
STS P08842 1/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 6/20 0.36
CYP2C9 P11712 3/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
ENPP3 O14638 2/20 0.36
ENPP1 P22413 2/20 0.36
ENPP2 Q13822 2/20 0.36
CYP3A4 P08684 3/20 0.35
TSHR P16473 2/20 0.35
CYP2C19 P33261 2/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25308618 1.00 CYP2D6 (0.40) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL25307250 1.00 CYP2D6 (0.40) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL23151947 0.88 CYP2D6 (0.40) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL3648014 0.86 CYP2D6 (0.39) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL3647966 0.86 CYP2D6 (0.39) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL22660615 0.85 STAT3 (0.40) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2
SCHEMBL22660613 0.85 STAT3 (0.40) CYP2D6STAT3CYP1A2KMT2ASMN1; SMN2
SCHEMBL25308312 0.85 KMT2A (0.38) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL25308313 0.85 KMT2A (0.38) CYP2D6STAT3STSCYP1A2KMT2A
SCHEMBL25308811 0.85 CYP2D6 (0.38) CYP2D6STAT3STSCYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028356-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS ABBVIE INC (US) 2026-01-29 US disclosed
US-20250066388-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS ABBVIE INC (US) 2025-02-27 US disclosed
US-11964990-B2 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors ABBVIE INC. (US) 2024-04-23 US disclosed
US-20230234971-A1 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors ABBVIE INC. (US) 2023-07-27 US disclosed
WO-2023141536-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS ABBVIE INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028356-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS BCL9L, BCL2L2, BCL2L1 CYP2D6 507/4885STAT3 2299/4885STS 2215/4885
US-20250066388-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS BCL9L, BCL2L1, BCL2L2 CYP2D6 981/4885STAT3 3219/4885STS 908/4885
US-20230234971-A1 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors BCL9L, BCL2L1, BCL2L2 CYP2D6 981/4885STAT3 3219/4885STS 908/4885
US-11964990-B2 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors BCL9L, BCL2L1, BCL9 CYP2D6 947/4885STAT3 3186/4885STS 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.